Anakinra
- Generic Name
- Anakinra
- Brand Names
- Kineret
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143090-92-0
- Unique Ingredient Identifier
- 9013DUQ28K
- Background
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the managemen...
- Indication
Anakinra is an interleukin-1 receptor antagonist indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA), in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). Anakinra can be used alone or in combin...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cryopyrin-associated Periodic Syndromes (CAPS), Deficiency of the interleukin-1 receptor antagonist, Idiopathic Recurrent Pericarditis, Moderately to Severely Active Rheumatoid Arthritis, Neonatal-Onset Multisystem Inflammatory Disease (NOMID), Systemic Juvenile Idiopathic Arthritis (SJIA)
- Associated Therapies
- -
Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Marc Y.Donath
- Target Recruit Count
- 18
- Registration Number
- NCT01771445
- Locations
- 🇨🇭
University Hospital of Basel, Division of Endocrinology, Basel, Switzerland
Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 80
- Registration Number
- NCT01566201
- Locations
- 🇬🇷
"Attikon" University General Hospital, Haidari, Athens, Attiki, Greece
Anakinra in Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 20
- Registration Number
- NCT01558375
- Locations
- 🇬🇷
2nd Department of Dermatology, ATTIKON University Hospital, Athens, Greece
🇬🇷4th Department of Internal Medicine, ATTIKON University Hospital, Athens, Greece
Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 12
- Registration Number
- NCT01542502
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Anakinra as a Treatment for Hydradenitis Suppurativa
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 6
- Registration Number
- NCT01516749
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT01477476
- Locations
- 🇺🇸
University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Childrens Hospital Colorado, Aurora, Colorado, United States
Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain
- First Posted Date
- 2011-11-08
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 13
- Registration Number
- NCT01466764
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
Anakinra for Behcet s Disease
- Conditions
- Interventions
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2017-05-12
- Target Recruit Count
- 6
- Registration Number
- NCT01441076
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal Volunteers
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Michelle Hernandez, MD
- Target Recruit Count
- 17
- Registration Number
- NCT01369017
- Locations
- 🇺🇸
UNC Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 11
- Registration Number
- NCT01300650
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.